Traduction de «multiple drug therapy » (Anglais → Français) :

multidrug therapy [ MDT | multiple drug therapy ]

therapy using pharmaceutical drugs | treatment using pharmaceutical drugs | drug therapy | pharmacotherapy

pharmacotherapy [ drug therapy | drug treatment | medication therapy | medicinal therapy ]

triple cocktail treatment | triple therapy | triple-combination therapy | triple-drug therapy

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

multiple addiction | multiple drug abuse | multi-substance abuse | panaddiction | polydrug use | poly-drug use | polysubstance abuse

multiple addiction [ multiple drug addiction ]

combination therapy | triple combination | triple-drug therapy

Definition: This category should be used when two or more psychoactive substances are known to be involved, but it is impossible to assess which substance is contributing most to the disorders. It should also be used when the exact identity of some or even all the psychoactive substances being used is uncertain or unknown, since many multiple drug users themselves often do not know the details of what they are taking. | misuse of drugs NOS

Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances

Some recent examples of therapeutic class reviews we have completed include drug therapies for relapsing-remitting multiple sclerosis and anti-thrombotic therapy for patients with atrial fibrillation.

For example, in Ontario, the government is paying pharmacists to help patients quit smoking and to optimize drug therapy for patients on multiple medications, those receiving home care, and patients with diabetes.

9. Urges Member States and the Commission to recognise and endorse the view that the cost-effectiveness of drug therapies used for patients with multiple sclerosis and other long-term chronic diseases should be measured not only through clinical trials but also through an assessment of improvement in the quality of life afforded by new treatment, which could have positive implications for savings in other sectors of social or welfare budgets;

L. L bearing in mind the need, beyond drug therapy, to develop effective and properly resourced services in care for multiple sclerosis patients which address their complex and lifelong requirements,